OOIR: Observatory of International Research

Papers

(The TQCC of Best Practice & Research Clinical Endocrinology & Metabolism is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
The novel concept of “Onco-Immuno-Endocrinology” led to the discovery of new clinical entity “paraneoplastic autoimmune hypophysitis”	114
Editorial Board	112
Editorial Board	78
Editorial Board	74
Genetics of pubertal timing	64
Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine	57
Growth hormone replacement in adults with cured acromegaly: Efficacy and safety	55
Recent progress in molecular classification of phaeochromocytoma and paraganglioma	53
Gonadectomy in individuals with a difference of sex development – For whom, when, why, and why not?	51
Menopausal hormone therapy for the management of osteoporosis	48
Regulation of bone mass: A splendid Orchestra	45
Polygenic risk scores for dyslipidemia and atherosclerotic cardiovascular disease: Progress toward clinical implementation	44
Coronavirus disease 2019 and vitamin D	44
Editorial Board	41
Rare forms of genetic steroidogenic defects affecting the gonads and adrenals	41
Sexual health and contraception in the menopause journey	40
The role of androgens in transgender medicine	40
Immune checkpoint inhibitor-related thyroid dysfunction	39
Prenatal exposure to phthalate esters and its impact on child development	39
Editorial Board	39
Optimal surgical approach for digestive neuroendocrine neoplasia primaries: Oncological benefits versus short and long-term complications	38
Remnant lipoprotein particles and cardiovascular disease risk	34
Cardiometabolic outcomes of early onset hypogonadism in males	34
Haematological actions of androgens	32
Acquired disorders of phosphaturia: Beyond tumor-induced osteomalacia	31

Molecular basis of symptomatic sporadic primary hyperparathyroidism: New frontiers in pathogenesis	31
Editorial Board	28
Safety of long-term use of daily and long-acting growth hormone in growth hormone-deficient adults on cancer risk	27
Epidemiology and risk factors for hypopituitarism due to traumatic brain injury	27
Endocrine-disrupting chemicals and behaviour: A high risk to take?	26
The effect of osteoporosis treatment on bone mass	26
Pathogenic role of Th17 cells in autoimmune thyroid disease and their underlying mechanisms	26
Medullary thyroid cancer - An update	26
Type 1 diabetes related to immune checkpoint inhibitors	26
Radioiodine therapy in the different stages of differentiated thyroid cancer	25
Metabolic complications and their mechanisms in patients with craniopharyngioma	25
Non-oestrogen-based and complementary therapies for menopause	24
Onco-immuno-endocrinology: An emerging concept that links tumor, autoimmunity, and endocrine disease	24
Safety of androgen therapy in men with prostate cancer	23
Hormone therapy for menopause and premature ovarian insufficiency	23
Immune checkpoint inhibitor-related hypophysitis	23
Pathophysiology of thyroid-associated orbitopathy	23
Approach to patients with elevated low-density lipoprotein cholesterol levels	23
Editorial Board	22
Personalized management for phaeochromocytomas and paragangliomas in Latin America: A genetic perspective	22
Best Practice and Research Clinical Endocrinology and Metabolism focusing on Growth Hormone Deficiency in Adults – New Perspectives	22
Best practice and research clinical endocrinology and metabolism issue on phaeochromocytomas and paragangliomas	22
The role of hormone therapy in urogenital health after menopause	21
Localization in primary hyperparathyroidism	21
Pathophysiology and diagnosis of neuroendocrine abnormalities in patients with traumatic brain injury	21
History of androgens and androgen action	21
Post cancer care in women with an increased risk of malignancy or previous malignancy: The use of hormone replacement therapy and alternative treatments	20
Genotype-phenotype correlations in Graves’ disease	20
Editorial Board	20
Editorial Board	20
Endocrine disrupting chemicals and bone	19
Genetics of anti-Müllerian hormone and its signaling pathway	19
“Micromegaly”: Acromegaly with apparently normal GH, an entity on its own?	18
Recent advances in algorithms predicting hemodynamic instability undergoing surgery for phaeochromocytoma and paraganglioma	18
Surgical outcomes in patients with acromegaly: Microscopic vs. endoscopic transsphenoidal surgery	18
Best practice & research clinical endocrinology & metabolism focusing on the menopause – Diagnostic and therapeutic strategies	18
Hyponatremia and bone pathophysiology: an integrated preclinical and clinical perspective	18
Hormone replacement in disorders of sex development, and long-term effects	17
Preface	17
Care quality improvement in differences of sex development	17
COVID-induced thyroid autoimmunity	16
The options for delayed surgery – Is there evidence available for delayed genitoplasty in differences/disorders of sex development?	16
Exercise and physical activity in individuals at risk of fracture	16
Preface	15
The epidemiology of disorders of sex development	15
Chemokines in thyroid autoimmunity	15
Editorial Board	15
Anaplastic thyroid cancer: An update	15
Genetic variants of gonadotrophins and their receptors: Impact on the diagnosis and management of the infertile patient	15